Shanghai Haohai Biological Technology Co., Ltd. (6826.HK)
HKD 26.85
(-1.65%)
HKD 26.85
(-1.65%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.08 Billion CNY | 9.92% |
| 2022 | 990.01 Million CNY | 11.23% |
| 2021 | 890.07 Million CNY | 57.69% |
| 2020 | 564.46 Million CNY | 13.23% |
| 2019 | 498.51 Million CNY | -17.04% |
| 2018 | 600.9 Million CNY | -15.2% |
| 2017 | 708.59 Million CNY | 0.15% |
| 2016 | 707.55 Million CNY | 352.18% |
| 2015 | 156.47 Million CNY | -0.8% |
| 2014 | 157.74 Million CNY | 107.21% |
| 2013 | 76.12 Million CNY | 29.07% |
| 2012 | 58.98 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.18 Billion CNY | 10.8% |
| 2024 Q1 | 1.07 Billion CNY | -1.61% |
| 2023 Q3 | 1.01 Billion CNY | -13.11% |
| 2023 FY | 1.08 Billion CNY | 9.92% |
| 2023 Q1 | 1.16 Billion CNY | 17.53% |
| 2023 Q2 | 1.16 Billion CNY | 0.0% |
| 2023 Q4 | 1.08 Billion CNY | 7.63% |
| 2022 Q4 | 990.01 Million CNY | 0.0% |
| 2022 Q3 | 990.01 Million CNY | -9.1% |
| 2022 Q2 | 1.08 Billion CNY | 0.0% |
| 2022 Q1 | 1.08 Billion CNY | 22.36% |
| 2022 FY | 990.01 Million CNY | 11.23% |
| 2021 Q1 | 652.6 Million CNY | 15.62% |
| 2021 Q2 | 652.6 Million CNY | -0.0% |
| 2021 Q3 | 655.14 Million CNY | 0.39% |
| 2021 Q4 | 890.07 Million CNY | 35.86% |
| 2021 FY | 890.07 Million CNY | 57.69% |
| 2020 Q3 | 558.87 Million CNY | -14.25% |
| 2020 FY | 564.46 Million CNY | 13.23% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 Q4 | 564.46 Million CNY | 1.0% |
| 2020 Q2 | 651.75 Million CNY | 0.0% |
| 2019 Q4 | 498.51 Million CNY | 0.0% |
| 2019 FY | 498.51 Million CNY | -17.04% |
| 2019 Q2 | 491.4 Million CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 Q2 | 681.18 Million CNY | 0.0% |
| 2018 Q4 | 600.9 Million CNY | 0.0% |
| 2018 Q1 | 681.18 Million CNY | -3.87% |
| 2018 Q3 | 600.9 Million CNY | -11.78% |
| 2018 FY | 600.9 Million CNY | -15.2% |
| 2017 Q3 | 724.05 Million CNY | 3.8% |
| 2017 FY | 708.59 Million CNY | 0.15% |
| 2017 Q1 | 697.52 Million CNY | -1.42% |
| 2017 Q2 | 697.52 Million CNY | 0.0% |
| 2017 Q4 | 708.59 Million CNY | -2.14% |
| 2016 Q1 | 184.79 Million CNY | 18.1% |
| 2016 Q3 | 536.15 Million CNY | 169.76% |
| 2016 Q2 | 198.75 Million CNY | 7.55% |
| 2016 FY | 707.55 Million CNY | 352.18% |
| 2016 Q4 | 707.55 Million CNY | 31.97% |
| 2015 Q3 | 140.99 Million CNY | -1.9% |
| 2015 Q2 | 143.72 Million CNY | 13.44% |
| 2015 Q1 | 126.69 Million CNY | -19.68% |
| 2015 FY | 156.47 Million CNY | -0.8% |
| 2015 Q4 | 156.47 Million CNY | 10.98% |
| 2014 Q1 | 94.02 Million CNY | 23.51% |
| 2014 FY | 157.74 Million CNY | 107.21% |
| 2014 Q3 | 139.23 Million CNY | 48.08% |
| 2014 Q2 | 94.02 Million CNY | 0.0% |
| 2014 Q4 | 157.74 Million CNY | 13.29% |
| 2013 Q3 | 76.12 Million CNY | 0.0% |
| 2013 Q4 | 76.12 Million CNY | 0.0% |
| 2013 Q1 | - CNY | 0.0% |
| 2013 FY | 76.12 Million CNY | 29.07% |
| 2012 FY | 58.98 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 152.81 Million HKD | -612.092% |
| CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 84.582% |